



Welcome to Aurore Life Sciences

Established in 2017, We are a pure-play Active Pharmaceutical Ingredient (API) company keen on delivering superior products in a regulatory compliant environment.

We are backed up with manufacturing facilities in India with a combined manufacturing capacity of 600 KL and our flagship facility in Hyderabad is approved with USFDA, EDQM, WHO Geneva, COFEPRIS, KFDA amongst other regulatory agencies. Our facilities, coupled with a dedicated R&D setup, complement our strategy to be a fully integrated API company with complete control of key starting materials, advanced intermediates and high-quality final product.

With a strong team of R&D experts that complements our strategy, Aurore is rapidly emerging as the most preferred API and key API intermediates supply partner for leading global pharmaceutical companies.

With a robust portfolio of niche and differentiated molecule spread across major therapeutic divisions, we are rapidly establishing ourselves as a reliable partner to serve unmet demands of the market.



Vision

To attain leadership position in the generic API arena by focusing on Innovation, Quality & Cost optimization.

Mission

To emerge as a most preferred API & Intermediate supply partner

Picking up the right assets to build scale in a pure play API business

Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in 2017 by a team with vast experience across the pharmaceutical value chain, the company is on a mission to become the most preferred partner for pharmaceuticals.

At Aurore, we aim to push the boundaries to manufacture and deliver high quality products that can be relied upon by both customers and regulators. Our thrust on rapidly adding capabilities have led us to acquire, integrate and expand our reach across the geographies.

Backed by a strong team of R&D experts, we work closely with our customers to innovate cost-effective processes and technologies, thus bringing down the cost of research and manufacturing. Our expertise led us to capitalizing on market-specific opportunities and delivering a competitive edge to our customers.

Infrastructure

Unit I

Facility Information

- **Location** – Aurore Pharmaceutical Pvt. Ltd. (Former Mylan Unit-III)
Phase IV, IDA, Jeedimetla, Hyderabad
- **Capacity** – 390 KI
- **Capabilities** – 5 Manufacturing blocks, 9 Clean rooms, 1 Solvent Recovery block
- **Facility** – Total Area: 43,856 Sq.Mtrs, Built up: 17,201 Sq.Mtrs, Green Belt: 5652 Sq.Mtrs
- **Approvals** – USFDA, EDQM, EMA, WHO Geneva, COFEPRIS, KFDA, ANVISA, TGA, AGES



Unit II

- Green field Manufacturing Site – Additional Capacities
- Location – Hyderabad
- Land Extent – 8 acres
- Projected capacities – Phase 1 – 250 KI and Phase 2 – 300 KI
- Status – Ready for Manufacturing during 2020

Reaction Capabilities

With a team that comprises of leading scientists who are aided by the most experienced and qualified chemists, our R&D is well-equipped with the infrastructure to support advanced research and innovation. We believe that R&D is the foundation for a harmonious growth at any pharma company; so research will always be at the heart of it.

- Alkylations
- Asymmetric Synthesis
- Cyanations
- Grignard
- Metallations
- Oxidation
- Acylation
- Carbohydrates
- Enzymatic Resolutions
- Halogenations (Br, Cl, POCl₃, PCl₃, PCl₅)
- Nitration
- Reduction – Catalytic (Ni, Pd/c, Pt/C, Rh, LAH, DIBAL, Diborane, NaCNBH₃)
- Amidations
- Chiral Alkylations
- Formylations
- High Temperature Reactions
- Organoborane
- Multistep Synthesis